After undergoing treatment for Stage 2 Hodgkins lymphoma, Hardee Bhavsar is on a journey to cross items off her bucket list ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

From his work at IMG Academy to being a GM with TBT’s Sideline Cancer, Coach Clapper’s one-day camp for high school players ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Researchers from the Schweitzer Biotech Company in Taiwan have created a serum which shows promising results for patients ...

Sunday’s game between the Packers and the Bengals was also the first game of October, where the NFL promotes “Crucial Catch ...

Severe gastrointestinal inflammation could occur in 2 percent to 3 percent of patients who receive Carvykti, the FDA has informed patients and doctors.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Medical oncologist Heather Parsons, MD, MPH, witnessed how cancer affects the entire family when her younger sister was ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 ...

The results highlight an in vivo patient-derived xenograft (PDX) model of relapsed/refractory T-PLL that reproduced key human clinicopathological features of the disease. In this model, SLS009 ...